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Abstract
Background—The prevalence of hepatitis C (HCV) and HIV among persons who inject drugs
(PWID) and the ability of these diseases to spread through injection networks are well documented
in urban areas. However, less is known about injection behaviors in rural areas.
Objectives—This study focuses on the association between the number of self-reported injection
partners with the PWID’s self-reported HCV and HIV status. Injection networks provide paths for
infection and information to flow, and are important to consider when developing prevention and
intervention strategies.

Author Manuscript

Methods—Respondent driven sampling was used to conduct 315 interviews with PWID in rural
Puerto Rico during 2015. Negative binomial regression was used to test for associations between
the number of self-reported injection partners and self-reported HCV and HIV statuses.
Multinomial logistic regression was used to test for associations with the participant’s selfreported HCV and HIV statuses.
Results—Self-reported HCV status is significantly associated with injection risk network size.
Injection partner networks of self-reported HCV− respondents are half what is reported by those
with a positive or unknown status. Self-reported HIV statuses are not associated with different
numbers of injection partners.

Author Manuscript

Conclusions—Smaller injection networks among those who self-reporta HCV− status suggests
that those who believe their status to be negative may take protective action by reducing their
injection network compared to those have a self-reported HCV+ or an unknown status. Although
the cross-sectional design of the study makes it difficult verify, such behavior has implications for
prevention programs attempting to prevent HCV transmission.
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The high prevalence of the hepatitis C virus (HCV) among people who inject drugs (PWID)
has been well documented, with estimates ranging from 60% to 80% globally (Nelson et al.,
2011), 50% to 60% in the United States mainland (Lansky et al., 2014) and up to 89% in
Puerto Rico (Reyes et al., 2006). HCV spreads through unsafe injection practices (Hagan et
al., 2001), can be symptomless for many years (D. J. Smith, Combellick, Jordan, & Hagan,
2015), and has been linked to social network characteristics of injectors (Brewer et al., 2006;
Sacks-Davis et al., 2012). HCV testing and counseling has become a readily accepted aspect
of interventions for PWID (CDC, 2013; WHO, n.d.). Such strategies assume that awareness
of a HCV status will influence injection risk behavior in a positive manner, reducing the
spread of the HCV virus (Aspinall et al., 2014; Cox et al., 2009). This assumption is based
on proven HIV intervention strategies which contain strong elements of testing information,
education, and counseling (MacArthur et al., 2014) to reduce risky behavior and further
disease transmission.

Author Manuscript
Author Manuscript

Social networks among PWID provide paths for infections and information to spread across.
In recent years studies have traced different viral genotypes of HCV across networks,
demonstrating how the spread of specific types of HCV are associated with network
characteristics (Pilon et al., 2011; Romano et al., 2010; Sacks-Davis et al., 2012). Here,
clusters of related HCV genotypes have been found within groups of injection partners
(Sacks-Davis et al., 2012) and also associated with disparate social networks of injection
partners in Brazil (Romano et al., 2010) and Canada (Pilon et al., 2011). Other studies
focused on the risk of HCV spread found that over 78% of injection partnerships (network
connections) involved behavior that could transmit HCV (Brewer et al., 2006); even
knowing someone else who injected increased a PWID’s odds of contracting HIV or HCV
(Latkin et al., 2011). Overall, networks seem to matter, but it remains largely unknown how
PWID injection risk network interactions may reflect local understandings and selfperceptions of one’s HCV status.

Author Manuscript

There is a lack of clear evidence on whether individual PWID risk network behavior may
reflect or respond to self-reported HCV status. Smith and colleagues (B. D. Smith et al.,
2013) found that PWID had higher odds of sharing injection materials when they shared the
same self-reported HCV status and other studies have found a variety of behavioral changes
associated with learning actual HCV status (Hahn, Evans, Davidson, Lum, & Page, 2010;
Kwiatkowski, Fortuin Corsi, & Booth, 2002; Vidal-Trécan, Coste, Varescon-Pousson,
Christoforov, & Boissonnas, 2000). In each of these studies the emphasis was on changes in
risk network behavior that accompanied a transition from self-reported to known HCV
status. However, these changes are not confined to learning about either a negative (Hagan et
al., 2006) or positive HCV result (Bruneau et al., 2014; Spelman et al., 2015; Vidal-Trécan
et al., 2000), and do not always reduce risk. Several studies have also found that moving
from self-reported to known HCV status was not associated with any changes in PWID risk
behavior (Miller, Mella, Moi, & Eskild, 2003; Ompad, Fuller, Vlahov, Thomas, & Strathdee,
2002). Further, there is some suggestion that important differences may exist between the
behavior of rural versus urban PWID with respect to self-reported HCV status and risk
partner selection (Duncan et al., 2017).
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Ambivalent reactions on the part of PWID to their HCV infection status are perhaps not
surprising. Given high HCV prevalence rates within the community, many PWID see the
acquisition of HCV as an inevitable side-effect of injecting drugs (Norden et al., 2009;
Nordén & Lidman, 2005; Rhodes & Treloar, 2008). Furthermore, considering that the
disease itself remains asymptomatic for many years, it is not unreasonable that PWID would
have different attitudes towards HCV than towards faster acting diseases such as HIV
(Lansky et al., 2014; Rhodes & Treloar, 2008). However, this difference in attitude remains
speculative without more evidence, leaving assumptions about the effectiveness of testing as
intervention unchallenged. Moving forward, it remains important to examine how current
risk network size may reflect past perceptions of one’s own HCV status.

Author Manuscript

In Puerto Rico, rural rather than urban communities seem to contribute disproportionately to
overall HIV infection rates (Colón-López, Ortiz, Banerjee, Gertz, & Garcia, 2013; Norman,
Dévieux, Rosenberg, & Malow, 2011; Pérez et al., 2010). Furthermore, over 20% of new
HIV diagnoses in Puerto Rico listed injection drug use as their cause, compared to 8.3% in
the continental United States (CDC, 2010). While similar surveillance data for HCV is not
available from this area, related transmission scenarios indicate equivalent (or greater) risk
for disparities in hepatitis (Abadie, Welch-Lazoritz, Gelpi-Acosta, Reyes, & Dombrowski,
2016). Given the recent rise of HCV in rural mainland United States (Suryaprasad et al.,
2014), a recent HIV outbreak in the Midwest (Peters et al., 2016), and a continuing increase
in rural drug use in general (Cicero, Ellis, Surratt, & Kurtz, 2014; Dombrowski, Crawford,
Khan, & Tyler, 2016), the experiences of PWID in rural Puerto Rico provide timely insight
into the trajectory of rural injection use in the contiguous United States.

Author Manuscript
Author Manuscript

The number of people a participant reports injecting with is an important aspect of an
injection network. It is an indicator of potential exposure and transmission of HCV and HIV
for both individuals and the larger network. Knowing the extent to which PWID are exposed
to injection network risk is critical to understanding disease spread within this community
(Dombrowski et al., 2013b, 2016b; Dombrowski, Curtis, Friedman, & Khan, 2013;
Friedman et al., 1997; Khan, Dombrowski, Saad, McLean, & Friedman, 2013; Neaigus,
Friedman, Kottiri, & Des Jarlais, 2001). We hypothesize that there will be a relationship
between a participant’s HCV or HIV status and their injection network size, and that this
relationship may not be the same for similar statuses—e.g., that HIV+ status will not
necessarily reflect the same association with risk network degree that an HCV+ status will.
Indeed, it is possible that, given documented expectations of HCV acquisition among PWID,
self-reported HCV+ status may be associated with higher network degree (rather than the
lower degree often seen among self-reported HIV+ PWID). While the studies cited above
have established the importance of the relationship between HIV status and risk network
size/degree, the same is not true for HCV status. Further, there is reason to believe that there
are significant differences in PWID response to self-reported HCV status when compared
with HIV (Abadie et al., 2016).
In what follows we use negative binomial regression to test whether self-reported HCV
status predicts larger risk network sizes for active injectors in rural Puerto Rico. While the
cross section nature of the data prevents us from examining how rural Puerto Rican PWID
react to a change in self-reported status (as a result of a recent test, for example), these data
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do allow us to investigate the association between self-reported status based on prior testing
and current overall risk network size. Where prior research in the area has pointed to
importance of self-reported HCV status on equipment sharing (Abadie et al., 2016), risk
partner selection (Duncan et al., 2017) and overall risk network topology (Coronado-García
et al., 2017); this analysis extends these investigations to the critical issue of overall risk
network size.

Methods
Sample recruitment

Author Manuscript

Interviews with 315 participants were completed between April 2015 and June 2015 in the
mountainous interior of Puerto Rico, 15-30 miles south of San Juan. Eligible participants
were alert, 18 years of age or older, and had injected drugs within the last 30 days. Female
injectors comprise 10% of the final analytical sample and the average age of participants
was 42, ranging between 18 and 70. Interviews were conducted by a postdoctoral
ethnographer alongside Puerto Rican staff working out of a storefront in one of the towns in
the region while working in close association with the region’s only syringe exchange
program. Transportation for participants from neighboring communities was facilitated by a
regular pattern of van pick-up/drop-off. Continuing relationships were maintained with
respondents in anticipation of planned additional rounds of data collection, including in situ
ethnographic research. After completing the questionnaire, participants were compensated
with $25. The study received IRB approval through the University of Nebraska-Lincoln
(IRB# 20131113844FB) and the University of Puerto Rico (IRB# A8480115).

Author Manuscript

Respondent driven sampling was used to recruit participants, starting with two interviews
(seeds) in each of the four focal towns. Seeds were recruited through collaboration with the
only needle exchange in the area. Participants who completed the survey were given three
referral coupons to pass out to other qualified individuals who had not previously
participated in the project. For every referral that completed the survey, the referee could
earn an additional $10. Respondent driven sampling differs from other methods in that the
researcher never knows the number of people who may have been given a coupon and
refused an interview. As such, traditional response rates are not applicable. Respondent
driven sampling is often preferred for hidden and hard-to-reach populations (Johnston,
Chen, Silva-Santisteban, & Raymond, 2013; Paquette, Bryant, & De Wit, 2011).

Author Manuscript

There is some risk of using a network based recruitment strategy to assess a network
outcome. However, standard methods of RDS analysis (Gile & Handcock, 2010; Spiller,
Cameron, & Heckathorn, 2012) were employed to control for network size in sample
correction. Furthermore, a range of individual risk network size measures were collected
from the sample and tested for the effects of “degree homophily” across a range of
participant attributes on sample recruitment bias. These were shown to be nonsignificant for
the variables used in this analysis, suggesting that the network size of the recruiter and the
recruit did not influence recruitment patterns in the data considered here.
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The questionnaire was interviewer-administered and based on the CDC National HIV and
Behavioral Surveillance (NHBS) of Injection Drug Users Round 3 Questionnaire version 13.
The NHBS is designed to produce regular estimates of the number and behavior of PWID in
23 urban areas in the United States; one of which is San Juan, Puerto Rico, an urban area
north of this project’s target rural area. The instrument asked questions about injection
behavior, prior HCV and HIV status and testing, and several other topics related to drug use
and HIV/HCV risk.

Author Manuscript

In addition, the project provided rapid testing for both HIV and HCV using INSTI Rapid
HIV antibody tests (Biolytical Laboratories) and OraQuick HCV Rapid antibody tests
(OraSure Technologies). Participants were compensated an additional $5 for each test. The
OraQuick HCV Rapid test is FDA approved and has demonstrated an accuracy rate greater
than 98% (FDA, 2011). The test is not confirmatory evidence of a current HCV infection, as
it cannot distinguish between antibodies which are present from a current or prior HCV
infection. Participants who tested positive for HCV or HIV antibodies were offered referral
and transportation to a primary care doctor for confirmatory testing and link-to-care.

Author Manuscript

The focal dependent variable for this article is the number of injection partners reported by
participants in the study’s four focal towns. These towns are located in a contiguous region
in the mountainous interior of Puerto Rico, 15-30 miles south of San Juan. Understanding
that PWID in the area are often highly mobile (due to uneven supply, local enforcement
trends, and financial reasons), participants were asked to estimate how many injection
partners they currently have in each of these towns (i.e., “How many injecting partners do
you have in town X”). Responses were summed to provide an overall number of injection
partners in the region.
The primary focal independent variables are self-reported HCV and self-reported HIV status
of the participant. These categories are defined by the participant’s report of having a prior
positive HCV or HIV test, a prior negative HIV or HCV test, or having never been tested for
either HIV or HCV. These results are classified as three categories for both HIV and HCV: a
self-reported positive, a self-reported negative, or an unknown status. During the current
survey, rapid antibody tests for HCV and HIV were administered to each participant in order
to provide a current antibody status for HIV and HCV, providing comparisons between selfreported and current status.

Author Manuscript

Other independent variables control for external factors, which may influence individual
numbers of risk partners, including number of towns lived in and number of towns injected
in within the region. These measure if the participant has ever lived or injected in any of the
four communities with possible values ranging from zero to four. In addition, measures of
the number of main sex partners and casual sex partners (as defined by NHBS) were
collected and summed across each location. Frequency of injection is measured as 1-3 times
per month (0), 1-6 times per week (1), 1-3 times per day (2), and 4 or more times per day
(3). Years injecting is measured by subtracting the participant’s age when they first report
injecting from their current age. Income is a dichotomous measure where (0) indicates
having earned or received less than $5,000 in the past year and (1) is earnings above $5,000.
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Education has three categories which are used as dummy variables: less than high school
(1), completed high school (2), and any further education past high school (3). Marital status
also has three categories: married or cohabiting (1); separated, divorced, or widowed (2);
and single (3). Additionally, sex (female = 1), age (mean centered in models), and born in
Puerto Rico (1) are used as controls in the models.
Data analysis

Author Manuscript

This article uses a two-pronged analytical strategy. Negative binomial regressions test the
associations of controls and independent variables with the number of injection partners.
This method is appropriate for dependent variables which are counts, over dispersed, and do
not have an overabundance of zeros (Long, 1997). Models progress in a stepwise fashion as
first controls and then possible explanatory variables are added in successive models. Results
from the negative binomial models are presented and discussed in terms of percent change
of the expected number of injection partners (i.e., incident rate ratios (Long & Freese,
2006)). Multinomial logistic regression is then used to examine other possible associations
between self-reported HCV and HIV statuses and the focal independent and control
variables. These models are used for dependent variables which are categorical and nominal
(Long, 1997). Results from the multinomial logistic regression models are presented and
discussed in terms of percent change of the relative risk of reporting a self-reported HCV or
HIV status (i.e., relative risk ratios (Long & Freese, 2006)). Due to limited missing data, the
final sample is 297 out of the original 315 (listwise deletion).

Results
Author Manuscript

In the final sample 90% of the participants are male and are on average 42 years old (Table
1). On average, participants reported 16 current injection partners across the focal locations,
had been injecting for almost 20 years, and currently inject 1-3 times per day. A majority of
the participants were born in Puerto Rico and reported receiving less than $5,000 in income
and assistance in the previous year. The unbalanced sex distribution of the sample is unlikely
to be an artifact of the RDS recruitment. Sample weighting from a range of RDS estimators
(Gile & Handcock, 2010; Spiller et al., 2012; Wejnert, 2009) showed low levels of both
degree and affiliation homophily by gender. The sampled distribution of gender is expected
to be within 2-3 percentage points of the region’s PWID population proportion.

Author Manuscript

Almost 80% of the participants tested HCV+ according to the rapid antibody tests conducted
at the end of the interview, but only 50% self-reported themselves as HCV positive before
the test (Table 2). Approximately half those with an unknown HCV status had a positive
HCV antibody test result. For those who reported a negative HCV result on their last test,
65% tested positive through the antibody test during the interview. Six percent of the sample
tested HIV+ in the rapid test and 4% knew they were HIV+ when they started. Two percent
of those who reported a self-reported HIV− status tested HIV+, and 6% of those who
reported an unknown status tested HIV+. Few participants with a self-reported positive
status received a negative antibody test (0% of HIV+ participants and 3% of HCV+
participants).
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Table 3 shows a series of negative binomial regression models that explore the association
between several factors and the expected number of injection partners. Models 1-3 show
simplified models where the association between self-reported HCV and HIV status are
examined individually and then in tandem with the expected number of injection partners. In
Model 1 the expected number of injection partners is higher for those with a self-reported
HCV unknown status (+88%, p < 0.01) and for those with a self-reported HCV+ status
(+146%, p < 0.001) compared to those with a self-reported HCV− status. Model 2 shows
that there is no significant association between self-reported HIV status and the expected
number of injection partners. In Model 3, which tests self-reported HCV and HIV status we
see a similar pattern from Model 1. Self-reported Unknown HCV and self-reported HCV+
status are associated with greater expected counts of injection partners (+106%, p < 0.01;
+ 156%, p < 0.001) compared to those with a self-reported HCV− status. Unlike prior
models, Model 3 shows a negative association between self-reported HIV+ (−54%, p < 0.05)
and the expected count of injection partners when compared to those with a self-reported
HIV− status.
Models 4 and 5 then test the association between self-reported HCV and HIV statuses and
the number of injection partners independently with controls. Here, reporting a self-reported
unknown HCV status is associated with a higher expected number of injection partners
(+82%, p < 0.01) than those reporting a self-reported HCV− status. Similarly, a self-reported
HCV+ status is associated with a much higher expected number of injection partners
(+117%, p < 0.001) than a HCV− status. There are no statistically significant associations
between self-reported HIV status and the expected number of injection partners found.

Author Manuscript

Model 6 of Table 3 includes all controls and predictors and shows that the expected number
of injection partners is significantly associated with being single compared to being married
or cohabiting (+46% p < 0.05). The expected number of injection partners also increases for
every year a participant has been injecting (+2%, p < 0.05) and for every additional focal
town ever injected in (+84%, p < 0.001). The expected number is higher for HCV unknown
(+102%, p < 0.001) and HCV+ self-reported statuses (+124%, p < 0.001) than for a selfreported HCV− status. The association between a self-reported HIV+ status and the
expected number of injection partners is only marginally significant in a full model with
controls compared to a self-reported unknown HIV status. The final model thus shows that
even under considerable controls, reported unknown and positive HCV statuses are
significantly associated with approximately double the expected injection network size than
those with a self-reported negative HCV status.

Author Manuscript

Although the differences in injection network size are clear, it is possible that there is a
common factor associated with these differences that then influences a participant’s selfreported HCV or HIV status. A multinomial logistic regression model tests the differences
between reporting self-reported HCV and HIV statuses (Table 4). For HCV, the only
significant association is that the relative risk of a participant reporting a self-reported HCV
unknown status rather than a HCV− status is 8.498 times greater when the participant
reports an HIV unknown status rather than a HIV− status. For self-reported HIV status, a
one year increase in the participant’s age is associated with an 8.4% (p < 0.05) lower relative
risk of that participant reporting a self-reported HIV unknown status than a HIV− status.
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Participants who are single compared to those who are currently together have a greater
relative risk (+231%, p < 0.05) of self-reporting an unknown HIV status compared to a HIV
− status. Those who self-reported an unknown HCV status have a greater relative risk
(+740%, p < 0.001) of reporting an unknown HIV status as well. Finally, participants who
inject more frequently are associated with a lower relative risk (−54%, p < 0.05) of reporting
a self-reported HIV+ status than a HIV− status. The majority of the controls and possible
other explanations for the relationships in Table 3 remain non-significant for both models.

Discussion

Author Manuscript

There are clear associations between the number of injection partners and self-reported HCV
status among rural PWID in Puerto Rico. On average, those who think that they are HCV
negative have half the expected number of current injection partners than those who are
either HCV positive or do not know their HCV status. These associations are different for
HIV, where there are no significant associations. Multinomial logistic regressions reveal few
differences associated with self-reported HCV status. Therefore, it is likely that the observed
differences in injection network sizes among these participants are associated with how they
view HCV and HIV.

Author Manuscript

In other settings, HCV is seen as omnipresent and an inevitable consequence of injecting
drugs by users themselves (Norden et al., 2009; Nordén & Lidman, 2005; Rhodes & Treloar,
2008), and PWID in rural Puerto Rico are unlikely to be an exception. In this context, it is
perhaps unsurprising that those who do not know their status have similar behavior to those
who self-report a HCV+ status. Many of those who do not know their status may assume
they are infected, and similarly, may assume that their potential risk partners are the same. A
lack of perceived risk may determine many interactions, especially when one considers that
HCV is perceived as a far less threatening infection than HIV (Rhodes & Treloar, 2008).
Under these conditions, a negative HCV status may motivate greater risk avoidance than a
positive or unknown one, and may prompt some self-protective action.

Author Manuscript

Though it’s limited, evidence for this has been discussed for other locations (Norden et al.,
2009; Vidal-Trécan et al., 2000). In their qualitative synthesis of the literature on HCV,
Rhodes and Treloar (2008) found a trend toward the individualization of responsibility as a
major theme raised by injectors when discussing their attitudes toward risk of HCV
infection. Such considerations were paramount in balancing health risk and drug intake to
avoid withdrawal while maintaining social ties critical to future drug access (Samuel R.
Friedman, Sandoval, Mateu-Gelabert, Meylakhs, & Jarlais, 2011). The situation is clearly
complex, but a simple solution for PWID who perceive their HCV status as negative may be
reducing the number of people they inject with. As smaller personal injection networks
entail less exposure risk.
Among injectors in rural Puerto Rican, self-reported HIV status was not associated with the
expected number of injection partners in models with controls. This stands against what
would be anticipated given evidence from other settings, that HIV positive PWID would be
more likely to disclose their status to injection partners (Nordén & Lidman, 2005), which
would in turn potentially reduce the number of possible injection partners. The absence of
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similar findings here may be due to the small number of people in the sample who reported
themselves to be HIV positive (4%), or it may reflect an artificial situation where HIV
positive PWIDs are, at times unwillingly, sent to the mainland United States for treatment
programs by local municipalities, and are thus removed from the environment of this study
(Perez Torruella, 2010).
In addition to self-reported HCV status, the expected number of injection partners was also
associated with the number of towns in the region a participant injected in, single
participants compared to married or cohabiting participants, and those who have been
injecting for a longer period of time. These associations collectively indicate that
participants with the largest injection networks would be those who are single, have injection
partners in multiple towns, have been injecting for many years, and who have a self-reported
HCV positive or unknown status.

Author Manuscript

Although many of these associations are quite substantial in size, they offer complex
guidance for the development of policy. Marital status or the ability of individuals to move
freely in their own country are not attributes which are easily modified through policy, nor
should they be. Furthermore, in places where most or even all PWID expect to already be (or
become) HCV positive and social pressure to truthfully disclose HCV status is low,
“testingas-intervention” strategies like those found to reduce risk among HIV positive PWID
may not be as effective in rural Puerto Rico.

Author Manuscript

Considering HCV to be a routine consequence of injecting among rural PWID may seem
unreasonable in many places given the seriousness of HCV infection, but in Puerto Rico,
where state provided insurance does not cover HCV care for HIV negative patients, these
expectations may reflect larger social disconcern. Here, we speculate that greater
expectations of engaging risk partners who are HCV negative could potentially change these
results, but this may require a larger change in the social value placed in HCV prevention.
The extent to which a lack of services contributes to this pattern of behavior and risk
assessments goes beyond the data available to us at this stage of the research, but we note
that syringe exchange access in the region is limited to a single mobile operation covering a
large rural area while attempting to serve a highly mobile population (López et al., 2015).
Limitations

Author Manuscript

Although we have outlined scenarios where injection network size is associated with health
statuses, injection frequency is not associated with either the size of injection networks or
the participant’s self-reported HCV or HIV status. A smaller injection network may reduce
the reach of a disease spreading within the larger network, but the frequency of injection sets
the pace for a disease to jump between two individuals (Mackesy-Amiti et al., 2011).
Limiting the size of an individual’s personal injection risk network may, therefore, not
influence the risk of transmission for a given dyad when injection frequency remains the
same.
These findings are also limited by the cross-sectional nature of the study. The lack of time
depth is, to some extent, addressed by looking at how self-reported disease status (which is
based on past HCV/HIV testing) is associated with differences in current behavior, thereby

Subst Use Misuse. Author manuscript; available in PMC 2019 June 07.

Habecker et al.

Page 10

Author Manuscript

associating prior attitudes with current practice. However, there is no substitute for a
longitudinal study. This limitation is compounded by evidence that HCV diagnoses in
particular can be highly variable in terms of quality, information, and empathy (Treloar,
Newland, Harris, Deacon, & Maher, 2010).
Another limitation is that the number of HIV+ participants is low and likely causing cell size
problems in Table 4. Our understanding, informed by research elsewhere in the United
States, is that low HIV prevalence levels are not simply a reflection of low HIV incidence in
Puerto Rico. As noted above, HIV+ PWID in rural Puerto Rico have reportedly been sent to
the mainland United States for treatment by local municipalities and may therefore be
uniquely underrepresented in this data (Perez Torruella, 2010).

Conclusion
Author Manuscript

Despite these limitations, the results presented here provide a clear view of how the number
of injection partners varies in association with knowledge of HCV status. In an environment
with high levels of HCV, it is the minority group, the ones who have not acquired HCV and
are aware of that status, that have the lowest number of injection partners. Those who are
HCV positive or unaware of their status have twice as many injection partners. Several
alternative explanations for larger injection networks such as age, years of injecting, the
number of towns a person has lived or injected in, and their number of sexual partners have
been included and the focal relationship persists. We view this as evidence that the
knowledge of a previous HCV− test (which defines an unknown from a negative status) is
associated with a decision to reduce injection network sizes, and a self-reported HCV+ or
unknown status does not.

Author Manuscript

If our desire is to reduce the spread of HCV (of which injection network size is a
component) then we suggest that practitioners attempt to confirm HCV− status when
possible and helping users develop safe injection practice before HCV is acquired. Although
this may appear similar to those involving outreach HIV testing, the latter is frequently
focused on identifying individuals with a positive status and helping them to minimize the
risk of HIV spread while managing the health consequences of their new diagnoses
(MacArthur et al., 2014).

Author Manuscript

The time frame during which a HCV− intervention can be staged is limited however,
especially among active injectors in HCV saturated environments such as that found in rural
PR. Similarly, a focus on locating PWID who have negative status later in their injection
careers (either due to clears, long-term behavior, or recent developments in HCV cures)
would require very active surveillance. The result, however, could help establish different
expectations toward the likelihood of future HCV infection. This in turn could potentially
lower the overall level of network risk through reducing the average number of network
injection partners throughout the network. Such a change can have implications for disease
transmission across a range of pathogens. Furthermore, as novel HCV treatment protocols
increase the number of mid-career HCV negatives, efforts to prevent reinfection grow more
important.
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Reaching injectors early and consistently can be challenging. Research has found that 78%
of injection partnerships involve behaviors with a high risk of HCV transmission (Brewer et
al., 2006) and that newer injectors quickly acquire HCV (E. R. Miller, Hellard, Bowden,
Bharadwaj, & Aitken, 2009). This provides a short window of time to deliver a HCV test.
Here, work with existing prevention programs such as syringe exchange programs (SEPs) is
likely to be critical to prevention success. SEPs are likely to recognize new injectors, but
seldom have available the means for field-testing for HCV due to financial limits or lack of
facilities. The results discussed here, however, indicate that for rural Puerto Rico, and
perhaps other rural locations as well, attempting to confirm HCV− statues alongside harm
reduction interventions already aimed at reaching rural populations may be effective for
HCV prevention.
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Table 1
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Descriptive statistics (n = 297).
Variables
Number of injection partners (current)
Female
Age

Mean/%

Std. D.

Min

Max

15.72

22.20

0

159

10%

0.30

0

1

41.89

10.17

18

70

Income: greater than or equal to $5,000

20%

0.40

0

1

Born in Puerto Rico

93%

0.26

0

1

Less than high school

47%

0.50

0

1

High school

35%

0.48

0

1

More than high school

18%

0.39

0

1

Together (married/cohabiting)

22%

0.41

0

1

Previously married (divorced/widowed/separated)

31%

0.46

0

1

single

47%

0.50

0

1

11%

0.31

0

1

Education

Marital status

Author Manuscript

Employed FT/PT/retired/student(ref = unemployed)
Number of years injecting

19.97

10.71

0

52

Frequency of injection

2.19

0.83

0

3

Number of focal towns lived in (ever)

1.20

0.59

0

4

Number of focal towns injected in (ever)

1.63

0.86

0

4

Number of main sex partners (current)

1.87

3.70

0

32

Number of casual sex partners (current)

2.69

5.23

0

41

HIV unknown

10%

0.30

0

1

Self-Reported Negative Status

86%

0.35

0

1

4%

0.20

0

1

6%

0.25

0

1

HCV unknown

23%

0.42

0

1

Self-reported negative status

27%

0.45

0

1

Self-reported positive status

49%

0.50

0

1

HCV+ antibody post survey test

78%

0.41

0

1

Self-reported HIV status

Author Manuscript

Self-reported positive status
HIV+ antibody post survey test
Self-reported HCV status

N

297

Author Manuscript
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Percent distribution of antibody test results by participant’s self-reported HCV or HIV status prior to the
antibody test (n = 297).
Negative
Self-reported HCV status

Positive

Total

HCV antibody test result

Unknown Status

46% (32)

54% (37)

23% (69)

Self-reported negative

34% (28)

66% (54)

27% (82)

3% (2)

97% (148)

50% (152)

21% (64)

79% (239)

Self-reported positive
Total
Self-reported HIV status

HIV antibody test result

Unknown status

93% (41)

Self-reported negative
Self-reported positive

Author Manuscript

Total

7% (3)

14% (44)

98% (254)

2% (4)

82% (258)

7% (1)

92% (12)

4% (13)

94% (296)

6% (19)

Author Manuscript
Author Manuscript
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Author Manuscript
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8.161

297

Intercept

N

297

16.492

297

8.298

297

1.417

297

1.377

2.967*

297

Reference

0.533+
[0.26, 1.03]

0.684
[0.45, 0.99]

Reference

2.235***
[1.62, 3.09]

2.023***
[1.36, 3.04]

1.033+
[0.99, 1.07]

0.997
[0.95, 1.05]

1.847***
[1.50, 2.24]

1.113
[0.84, 1.47]

1.055
[0.90, 1.22]

1.024*
[1.00, 1.05]

1.457*
[1.04, 2.08]

1.133
[0.76, 1.66]

Reference

0.984
[0.96, 1.00]

0.924
[0.57, 1.45]

(6)

Reference

Reference

Reference

HIV Self-Reported Negative Status (reference)

0.621
[0.30, 1.22]

0.456*
[0.22, 0.96]

0.561
[0.26, 1.20]

HIV Self-Reported Positive Status

0.751
[0.48, 1.05]

Reference

2.168***
[1.57, 2.99]

0.764
[0.48, 1.21]

0.798
[0.52, 1.22]

HIV Unknown Status

Reference

Reference

HCV Self-Reported Negative Status (reference)

1.031+
[0.99, 1.07]

# of Casual Sex Partners (current)

2.559***
[1.81, 3.61]

1.038*
[1.00, 1.08]

0.997
[0.95, 1.05]

# of Main Sex Partners (current)

2.458***
[1.74, 3.47]

1.000
[0.95, 1.05]

1.892***
[1.55, 2.32]

# of Focal Towns Injected In (ever)

HCV Self-Reported Positive Status

1.833***
[1.49, 2.24]

1.078
[0.81, 1.43]

# of Focal Towns Lived In (ever)

1.817**
[1.24, 2.67]

1.079
[0.81, 1.44]

1.057
[0.91, 1.23]

Frequency of Injection

2.063**
[1.33, 3.21]

1.028**
[1.01, 1.05]

1.022*
[1.00, 1.04]

# of Years Injecting

1.879**
[1.25, 2.82]

1.319
[0.93, 1.90]

1.405+
[0.99, 1.99]

Single

HCV Unknown Status

1.009
[0.68,1.49]

1.066
[0.72, 1.57]

Previously Married

1.050
[0.90, 1.22]

Reference

Reference

Together: Married or Cohabiting (reference)

0.858
[0.52,1.37]

(5)

0.984
[0.96,1.01]

(4)

0.985
[0.96, 1.01]

(3)

Age (mean centered)

(2)
0.924
[0.58, 1.48]

(1)

Female

Variables

Negative binomial regression predicting the number of injector partners by self-reported HCV and HIV status with controls (n = 297).

Author Manuscript

Table 3
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0.001

(2)
0.01

(3)

p < 0.10,

0.05

(4)
0.04

(5)
0.05

(6)

p < 0.001 Not shown are non-significant coefficients for being born in Puerto Rico, income, education, and current employment status.

***

p < 0.01,

**

p < 0.05,

*

+

Coefficients are presented as incident rate ratios and 95% confidence intervals are presented below:

Pseudo

0.01

Author Manuscript
(1)

Author Manuscript

R2

Author Manuscript

Variables
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Multinomial logistic regression models predicting perceived HCV and HIV status (n = 297).
HVC self-reported status (ref: Negative)

HIV self-reported status (ref: Negative)

Variables

Unknown

Positive

Unknown

Positive

Female

0.876
[0.24, 3.15]

1.104
[0.43, 2.85]

0.386
[0.07, 2.18]

2.254
[0.27, 18.9]

Age (mean centered)

0.973
[0.92, 1.03]

0.994
[0.96, 1.03]

0.916*
[0.85, 0.99]

1.063
[0.96, 1.18]

Reference

Reference

Reference

Reference

Previously Married

0.577
[0.20, 1.67]

0.789
[0.34, 1.81]

3.111+
[0.86, 11.3]

0.349
[0.05, 2.35]

Single

0.794
[0.30, 2.07]

1.141
[0.52, 2.48]

3.308*
[1.02, 10.7]

0.552
[0.09, 3.25]

# of Years Injecting

1.024
[0.97, 1.08]

1.027
[0.99, 1.07]

1.041
[0.98, 1.12]

1.047
[0.96, 1.14]

# of Focal Towns Lived In (ever)

1.044
[0.53, 2.07]

0.919
[0.54, 1.55]

1.180
[0.57, 2.45]

0.805
[0.22, 2.96]

# of Focal Towns Injected In (ever)

1.028
[0.62, 1.70]

1.394+
[0.99, 2.07]

0.781
[0.46, 1.33]

0.752
[0.29, 1.97]

Frequency of Injection

1.280
[0.81, 2.03]

1.067
[0.76, 1.50]

1.047
[0.64, 1.71]

0.460*
[0.21, 0.99]

# of Main Sex Partners (current)

0.981
[0.84, 1.15]

1.064
[0.95, 1.20]

0.895
[0.64, 1.71]

0.746
[0.43, 1.29]

# of Casual Sex Partners (current)

1.053
[0.95, 1.16]

0.990
[0.91, 1.08]

1.056
[0.97, 1.15]

1.100
[0.90, 1.34]

HIV: Unknown Status

8.498***
[2.82, 25.6]

1.578
[0.51, 4.90]

HIV: Self-Reported Positive Status

0.000
[0.00, 0.00]

1.916
[0.46, 7.96]

Reference

Reference

HCV: Unknown Status

8.397***
[2.77, 25.5]

0.000
[0.00, 0.00]

HCV: Self-Reported Positive Status

1.596
[0.51, 5.01]

3.152
[0.57, 17.6]

Reference

Reference

0.075

2.824

Together: Married or Cohabiting (reference)

Author Manuscript
Author Manuscript

HIV: Self-Reported Negative Status (reference)

HCV: Self-Reported Negative Status (reference)
Intercept

0.085+

0.413

N

297

297

Pseudo R2

0.11

0.25

Coefficients are presented as relative risk ratios and 95% confidence intervals are presented below:

+
p < 0.10,
*

Author Manuscript

p < 0.05,

**

p < 0.01,

***

p < 0.001. Not shown are non-significant coefficients for being born in Puerto Rico, income, education, and current employment status.
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